Available as an add-on in conjunction with, or after, a Diagnostic/Prognostic Profile result has been reported by Genoptix or client. Markers performed by flow cytometry include cCD3, CD1a, CD3, CD4, CD8, CD10, CD45 and TdT.

The BCR-ABL MRDx® TFR Monitoring Test is a companion diagnostic for Chronic Myeloid Leukemia (CML) patients in the chronic phase (CP) being treated with nilotinib who may be candidates for treatment discontinuation and monitoring of treatment-free remission (TFR).

MRDx® is a registered trademark of MolecularMD

Cytogenetic abnormalities commonly associated with high-grade B-cell non-Hodgkin lymphomas (NHL) are detected by fluorescence in situ hybridization (FISH). Probes for BCL6 (3q27.3), IRF4-DUSP22 (6p25.3), MYC (8q24.21), IGH/BCL2 t(14;18)) are included in the B-NHL – High Grade FISH Profile (Enriched). B-cells are enriched from patient’s specimen using immunomagnetic enrichment technology with CD19/CD20 antibodies.

Cytogenetic abnormalities commonly associated with acute lymphoblastic leukemia (ALL) are detected by fluorescence in situ hybridization (FISH). Probes for TCF3/PBX1 t(1;19), BCR/ABL1-ASS1 t(9;22), CDKN2A (9p21.3), KMT2A (MLL)(11q23.3), ETV6/RUNX1 t(12;21)/(iAMP21), IGH (14q32.3), TP53 (17p13.1) are included in the ALL FISH Profile.

A tech-only 25-marker screening profile for peripheral blood specimens. An evaluation of specimen adequacy and cellular integrity will also be performed. Markers include CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD13, CD14, CD16, CD19, CD20, CD23, CD34, CD38, CD45, CD56, CD57, CD103, CD117, FMC 7, HLADR, Kappa, and Lambda.

A tech-only 20-marker screening profile for fresh tissue specimens. An evaluation of specimen adequacy and cellular integrity will also be performed. Markers include CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD14, CD19, CD20, CD23, CD34, CD38, CD45, CD56, CD57, CD200, FMC 7, Kappa and Lambda.

Cytogenetic abnormalities commonly associated with multiple myeloma (MM) are detected by fluorescence in situ hybridization (FISH). Probes for CKS1B-CDKN2C (1p32.3/1q21.3), 5q (5q-/-5/+5), 13q (13q-/-13), TP53 (17p13.1), IGH/FGFR3 t(4;14), IGH/CCND1 t(11;14), IGH/MAF t(14;16), IGH/MAFB t(14;20) are included in the Myeloma FISH Profile.

Cytogenetic abnormalities commonly associated with B-cell non-Hodgkin lymphomas (NHL) are detected by fluorescence in situ hybridization (FISH). Probes for BCL6 (3q27.3), 6q (6q-/-6), MYC (8q24.21), IGH/CCND1 t(11;14), IGH/BCL2 t(14;18) and MALT1 (18q21) are included in the B-NHL FISH Profile.

Cytogenetic abnormalities commonly associated with high-grade B-cell non-Hodgkin lymphomas (NHL) are detected by fluorescence in situ hybridization (FISH). Probes for BCL6 (3q27.3), IRF4-DUSP22 (6p25.3), MYC (8q24.21), IGH/BCL2 t(14;18)) are included in the B-NHL High-Grade FISH Profile (Enriched). B-cells are enriched from patient’s specimen using immunomagnetic enrichment technology with CD19/CD20 antibodies.

A tech-only 25-marker screening profile for myeloma. An evaluation of specimen adequacy and cellular integrity will also be performed. Markers include cKappa, cLambda, CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD13, CD14, CD16, CD19, CD20, CD34, CD38, CD45, CD56, CD57, CD117, CD138, HLADR, Kappa, and Lambda.